Equities
Ultragenyx Shares Rise 10% Following Approval of First Therapy for MPS IIIA
17 Sep 2026
1 minute
by Octrado Team
Ultragenyx Shares Rise 10% Following Approval of First Therapy for MPS IIIA

Shares of Ultragenyx Pharmaceutical rose sharply on Thursday, September 17, 2026, after the U.S. Food and Drug Administration (FDA) issued a key favourable decision. The approval of its new treatment, Fayuvi, provides the first genuine treatment option for children with this rare inherited disorder.

 

A Breakthrough in Treatment Options

Fayuvi makes history as the first gene therapy and the only available treatment for paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), better known as Sanfilippo syndrome type A. This severe disorder progressively damages the brain and the entire nervous system, and until now, no therapy had been available to alter its adverse course. The market responded immediately to the news, with Ultragenyx Pharmaceutical shares surging 10% during the trading day. The significance of this therapeutic breakthrough is also reflected in the FDA’s decision to grant the treatment Orphan Drug, Fast Track and Breakthrough Therapy designations.

 

Long-Term Losses Remain Substantial

The investor response provides a much-needed boost after an extended period of decline. Ultragenyx Pharmaceutical Inc. shares have lost approximately 85% of their value over the past five years, making the latest gains a promising first step towards a turnaround. The approval of Fayuvi is not only a significant medical milestone but also provides the company with a strong foundation that could help reverse its negative stock market trajectory.

 

Ultragenyx Pharmaceutical Inc Stock Price Performance Over the Past Five Years [USD]

(Source: CNBC)

 

Replacing a Faulty Gene

The therapy works through modern genetic technology. Fayuvi is administered as a single intravenous infusion, using a modified adeno-associated virus serotype 9 to deliver a fully functional copy of the SGSH gene directly into cells. This enables them to begin producing sulfamidase, an enzyme that patients lack or have at critically low levels. The safety and efficacy of this approach were demonstrated in an open-label, single-arm, multicentre study involving children aged 2 to 5, in which treated patients maintained or even improved their cognitive function compared with a historical control group of untreated children.

 

Efficacy Comes with Risks

As with any breakthrough treatment, promising results come with safety warnings. Adverse reactions reported in more than 5% of patients included elevated liver enzymes and amylase, nausea, vomiting, fever, decreased appetite, and reduced white blood cell and platelet counts. The FDA also specifically highlights the risk of thrombotic microangiopathy and potential long-term risks, such as tumour development associated with the integration of new genetic material.

 

Administration Requires Specialist Supervision

Given these risks, the introduction of the therapy into clinical practice comes with strict requirements for comprehensive care. Patients must begin taking corticosteroids one day before the infusion and continue treatment for at least eight weeks. The medicine must be administered exclusively in a specialised healthcare facility fully equipped to manage potential infusion reactions. The arrival of this new treatment option therefore places particular emphasis not only on efficacy but also on careful risk prevention and management during administration and subsequent care.

 

This marketing material is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any financial instruments.

 

Trading in securities involves significant risk and may not be suitable for all investors. Prices of securities may fluctuate significantly and may result in a total loss of your investment. Investors should be aware that losses may exceed potential profits when buying and selling securities. In certain market conditions, you may sustain losses that exceed your initial investment. Securities and contracts for differences are complex financial instruments that require a high level of knowledge and understanding. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.

 

 

 


Source: https://www.investing.com/news/stock-market-news/ultragenyx-stock-surges-10-on-fda-approval-for-gene-therapy-93CH-4906265
Recommend articles for you
Siemens Energy Gets Paid Before It Delivers
Equities
Siemens Energy Gets Paid Before It Delivers
Building a gas turbine or a transformer requires money before the finished equipment reaches its cus...
13 Nov 2026
5 minutes
by Octrado Team
Alphabet Shares Plunge as AI Spending Bites
Equities
Alphabet Shares Plunge as AI Spending Bites
Alphabet’s Class A shares fell nearly 13% on October 29 after Google parent’s third-quarter results...
02 Nov 2026
10 minutes
by Octrado Team
SK Hynix's Real Problem Is Currency, Not Demand
Equities
SK Hynix's Real Problem Is Currency, Not Demand
SK Hynix reported third-quarter revenue of 104.6 trillion won and operating profit of 83.3 trillion...
30 Oct 2026
8 minutes
by Octrado Team
Join our newsletter
Join Octotrado today and start trading like a pro with free capital at your fingertips. Start trading now!
Follow us on:
We accept:
© 2026 Octrado. All Rights Reserved
Octrado is a brand of Octrado Ltd. a limited liability company regulated as a Securities Dealer by the Seychelles Financial Services Authority of Seychelles ("FSA") with license number SD013 to carry out certain categories of financial investment business as permitted under the Seychelles Securities Act 2007.
Octrado does not offer its services to the residents of certain jurisdictions such as: Afghanistan, Cuba, Crimea, Israel, Sudan, North Korea, Ethiopia, Iran, Bosna and Herzegovina, Iraq, Lao People's Democratic Republic, Syria, Uganda, Vanuatu and Yemen.
None of the services provided on Octrado webpage constitute regulated investment services. Octrado does not provide trading with real stocks, commodities, indices, derivatives or other financial instruments. No information or material posted on this webspage should be construed as any type of investment advice, investment research and/or a solicitation for any transactions and it does not guarantee or predict future performance.